![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RJ Lukas
Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona.
Studies were conducted on high-affinity, nicotinic binding of 3H- labeled acetylcholine ([3H]ACh) to membrane preparations derived from the TE671 human clonal line and the PC12 rat pheochromocytoma. For comparative purposes and to extend results obtained by others in previous studies, [3H]ACh binding to membrane preparations derived from rat brain and from the electric tissue of Torpedo californica also was characterized. In each case, specific [3H]ACh binding (KD values of about 10 nM) could be fit by linear Scatchard and logit-log curves (slope of the latter of about 1.0) indicating that binding occurred to a single class of noninteracting sites, except that a better fit to PC12 cell membrane binding data was obtained using a two-site model. Quantitation of high-affinity binding sites for [3H]ACh and radiolabeled alpha-bungarotoxin and studies of unlabeled toxin competition for [3H]ACh binding indicated that toxin and agonist sites on TE671 cell or Torpedo membranes were closely related, but that toxin and agonist sites had limited or no physical overlap on PC12 cell or rat brain membranes. Generally, drugs of the bisonium and bis-choline series were more effective inhibitors of [3H]ACh binding to TE671 cell or Torpedo membranes, but nicotine and cytisine interacted with PC12 cell or rat brain sites with highest affinity. These results suggest that nicotinic agonists bind with high affinity to specific, membrane- bound sites on presumptive nicotinic ACh receptors expressed on each of these preparations. Moreover, the data are consistent with structural heterogeneity of these nicotinic receptor sites.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  S. Fraterman, T. S. Khurana, and N. A. Rubinstein Identification of acetylcholine receptor subunits differentially expressed in singly and multiply innervated fibers of extraocular muscles. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3828 - 3834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Peng, J. D. Fryer, R. S. Hurst, K. M. Schroeder, A. A. George, S. Morrissy, V. E. Groppi, S. S. Leonard, and R. J. Lukas High-Affinity Epibatidine Binding of Functional, Human {alpha}7-Nicotinic Acetylcholine Receptors Stably and Heterologously Expressed de Novo in Human SH-EP1 Cells J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 24 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Eaton, J.-H. Peng, K. M. Schroeder, A. A. George, J. D. Fryer, C. Krishnan, L. Buhlman, Y.-P. Kuo, O. Steinlein, and R. J. Lukas Characterization of Human {alpha}4{beta}2-Nicotinic Acetylcholine Receptors Stably and Heterologously Expressed in Native Nicotinic Receptor-Null SH-EP1 Human Epithelial Cells Mol. Pharmacol., December 1, 2003; 64(6): 1283 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ke, C. M. Eisenhour, M. Bencherif, and R. J. Lukas Effects of Chronic Nicotine Treatment on Expression of Diverse Nicotinic Acetylcholine Receptor Subtypes. I. Dose- and Time-Dependent Effects of Nicotine Treatment J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 825 - 840. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Marks, K. W. Smith, and A. C. Collins Differential Agonist Inhibition Identifies Multiple Epibatidine Binding Sites in Mouse Brain J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 377 - 386. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Chen and J. W. Patrick The alpha -Bungarotoxin-binding Nicotinic Acetylcholine Receptor from Rat Brain Contains Only the alpha 7 Subunit J. Biol. Chem., September 19, 1997; 272(38): 24024 - 24029. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
